FOXP1 and Estrogen Signaling in Breast Cancer

Vitamins and Hormones

Volumn 93, Issue , 2013, Pages 203-212

  Ijichi, Nobuhiro ^a   Ikeda, Kazuhiro ^a   Horie Inoue, Kuniko ^a   Inoue, Satoshi ^a,b  

^a SAITAMA MEDICAL UNIVERSITY   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

Author keywords

Breast cancer; Estrogen receptor; Forkhead box transcription factor; FOXA1; FOXP1; Tamoxifen

Indexed keywords

EID: 84880299662     PISSN: 00836729     EISSN: None     Source Type: Book Series    
DOI: 10.1016/B978-0-12-416673-8.00006-X     Document Type: Chapter

References (43)

1. Annicotte J.S., Chavey C., Servant N., Teyssier J., Bardin A., Licznar A., et al. The nuclear receptor liver receptor homolog-1 is an estrogen receptor target gene. Oncogene 2005, 24:8167-8175.
2. Badve S., Turbin D., Thorat M.A., Morimiya A., Nielsen T.O., Perou C.M., et al. FOXA1 expression in breast cancer-Correlation with luminal subtype A and survival. Clinical Cancer Research 2007, 13:4415-4421.
3. Banham A.H., Beasley N., Campo E., Fernandez P.L., Fidler C., Gatter K., et al. The FOXP1 winged helix transcription factor is a novel candidate tumor suppressor gene on chromosome 3p. Cancer Research 2001, 61:8820-8829.
4. Banham A.H., Boddy J., Launchbury R., Han C., Turley H., Malone P.R., et al. Expression of the forkhead transcriptional factor FOXP1 is associated both with hypoxia inducible factors (HIFs) and the androgen receptor in prostate cancer but is not directly regulated by androgens or hypoxia. Prostate 2007, 67:1091-1098.
5. Banham A.H., Connors J.M., Brown P.J., Cordell J.L., Ott G., Sreenivasan G., et al. Expression of the FOXP1 transcription factor is strongly associated with inferior survival in patients with diffuse large B-cell lymphoma. Clinical Cancer Research 2005, 11:1065-1072.
6. Barrans S.L., Fenton J.A., Banham A., Owen R.G., Jack A.S. Strong expression of FOXP1 identifies a distinct subset of diffuse large B-cell lymphoma (DLBCL) patients with poor outcome. Blood 2004, 104:2933-2935.
7. Bates G.J., Fox S.B., Han C., Launchbury R., Leek R.D., Harris A.L., et al. Expression of the forkhead transcription factor FOXP1 is associated with that of estrogen receptorβ in primary invasive breast carcinomas. Breast Cancer Research and Treatment 2008, 111:453-459.
8. Carroll J.S., Brown M. Estrogen receptor target gene: An evolving concept. Molecular Endocrinology 2006, 20:1707-1714.
9. Carroll J.S., Liu X.S., Brodsky A.S., Li W., Meyer C.A., Szary A.J., et al. Chromosome-wide mapping of estrogen receptor binding reveals long-range regulation requiring the forkhead protein FoxA1. Cell 2005, 122:33-43.
10. Carroll J.S., Meyer C.A., Song J., Li W., Geistlinger T.R., Eeckhoute J., et al. Genome-wide analysis of estrogen receptor binding sites. Nature Genetics 2006, 38:1289-1297.
11. Craig V.J., Cogliatti S.B., Imig J., Renner C., Neuenschwander S., Rehrauer H., et al. Myc-mediated repression of microRNA-34a promotes high grade transformation of B-cell lymphoma by dysregulation of FoxP1. Blood 2011, 117:6227-6236.
12. Fox S.B., Brown P., Han C., Ashe S., Leek R.D., Harris A.L., et al. Expression of the forkhead transcription factor FOXP1 is associated with estrogen receptor α and improved survival in primary human breast carcinomas. Clinical Cancer Research 2004, 10:3521-3527.
13. Ghosh M.G., Thompson D.A., Weigel R.J. PDZK1 and GREB1 are estrogen-regulated genes expressed in hormone-responsive breast cancer. Cancer Research 2000, 60:6367-6375.
14. Goatly A., Bacon C.M., Nakamura S., Ye H., Kim I., Brown P.J., et al. FOXP1 abnormalities in lymphoma: Translocation breakpoint mapping reveals insights into deregulated transcriptional control. Modern Pathology 2008, 21:902-911.
15. Grange T., Roux J., Rigaud G., Pictet R. Cell-type specific activity of two glucocorticoid responsive units of rat tyrosine aminotransferase gene is associated with multiple binding sites for C/EBP and a novel liver-specific nuclear factor. Nucleic Acids Research 1991, 19:131-139.
16. Habashy H.O., Powe D.G., Rakha E.A., Ball G., Paish C., Gee J., et al. Forkhead-box A1 (FOXA1) expression in breast cancer and its prognostic significance. European Journal of Cancer 2008, 44:1541-1551.
17. Hall J.M., McDonnell D.P. Coregulators in nuclear estrogen receptor action: From concept to therapeutic targeting. Molecular Interventions 2005, 5:343-357.
18. Hoeller S., Schneider A., Haralambieva E., Dirnhofer S., Tzankov A. FOXP1 protein overexpression is associated with inferior outcome in nodal diffuse large B-cell lymphomas with non-germinal centre phenotype, independent of gains and structural aberrations at 3p14.1. Histopathology 2010, 57:73-80.
19. Holmes K.A., Hurtado A., Brown G.D., Launchbury R., Ross-Innes C.S., Hadfield J., et al. Transducin-like enhancer protein 1 mediates estrogen receptor binding and transcriptional activity in breast cancer cells. Proceedings of the National Academy of Sciences of the United States of America 2012, 109:2748-2753.
20. Hurtado A., Holmes K.A., Ross-Innes C.S., Schmidt D., Carroll J.S. FOXA1 is a key determinant of estrogen receptor function and endocrine response. Nature Genetics 2011, 43:27-33.
21. Ijichi N., Shigekawa T., Ikeda K., Horie-Inoue K., Shimizu C., Saji S., et al. Association of double-positive FOXA1 and FOXP1 immunoreactivities with favorable prognosis of tamoxifen-treated breast cancer patients. Hormones & Cancer 2012, 3:147-159.
22. Kastner P., Krust A., Turcotte B., Stropp U., Tora L., Gronemeyer H., et al. Two distinct estrogen-regulated promoters generate transcripts encoding the two functionally different human progesterone receptor forms A and B. EMBO Journal 1990, 9:1603-1614.
23. Laganière J., Deblois G., Lefebvre C., Bataille A.R., Robert F., Giguère V. From the cover: Location analysis of estrogen receptor α target promoters reveals that FOXA1 defines a domain of the estrogen response. Proceedings of the National Academy of Sciences of the United States of America 2005, 102:11651-11656.
24. Lai K., Harnish D.C., Evans M.J. Estrogen receptor α regulates expression of the orphan receptor small heterodimer partner. Journal of Biological Chemistry 2003, 278:36418-36429.
25. Li S., Weidenfeld J., Morrisey E.E. Transcriptional and DNA binding activity of the Foxp1/2/4 family is modulated by heterotypic and homotypic protein interactions. Molecular and Cellular Biology 2004, 24:809-822.
26. Lupien M., Eeckhoute J., Meyer C.A., Wang Q., Zhang Y., Li W., et al. FoxA1 translates epigenetic signatures into enhancer-driven lineage-specific transcription. Cell 2008, 132:958-970.
27. Mehta R.J., Jain R.K., Leung S., Choo J., Nielsen T., Huntsman D., et al. FOXA1 is an independent prognostic marker for ER-positive breast cancer. Breast Cancer Research and Treatment 2012, 131:881-890.
28. Perou C.M., Sørlie T., Eisen M.B., van de Rijn M., Jeffrey S.S., Rees C.A., et al. Molecular portraits of human breast tumours. Nature 2000, 406:747-752.
29. Platet N., Cathiard A.M., Gleizes M., Garcia M. Estrogens and their receptors in breast cancer progression: A dual role in cancer proliferation and invasion. Critical Reviews in Oncology/Hematology 2004, 51:55-67.
30. Prown P.J., Ashe S.L., Leich E., Burek C., Barrans S., Fenton J.A., et al. Potentially oncogenic B-cell activation induced smaller isoforms of FOXP1 are highly expressed in the activated B cell-like subtype of DLBCL. Blood 2008, 111:2816-2824.
31. Rayoo M., Yan M., Takano E.A., Bates G.J., Brown P.J., Banham A.H., et al. Expression of the forkhead box transcription factor FOXP1 is associated with oestrogen receptor alpha, oestrogen receptor beta and improved survival in familial breast cancers. Journal of Clinical Pathology 2009, 62:896-902.
32. Ross-Innes C.S., Stark R., Teschendorff A.E., Holmes K.A., Ali H.R., Dunning M.J., et al. Differential oestrogen receptor binding is associated with clinical outcome in breast cancer. Nature 2012, 481:389-393.
33. Sagaert X., De Paepe P., Libbrecht L., Vanhentenrijk V., Verhoef G., Thomas J., et al. Forkhead box protein P1 expression in mucosa-associated lymphoid tissue lymphomas predicts poor prognosis and transformation to diffuse large B-cell lymphoma. Journal of Clinical Oncology 2006, 24:2490-2497.
34. Schuur E.R., Loktev A.V., Sharma M., Sun Z., Roth R.A., Weigel R.J. Ligand-dependent interaction of estrogen receptor-α with members of the forkhead transcription factor family. Journal of Biological Chemistry 2001, 276:33554-33560.
35. Shigekawa T., Ijichi N., Ikeda K., Horie-Inoue K., Shimizu C., Saji S., et al. FOXP1, an estrogen-inducible transcription factor, modulates cell proliferation in breast cancer cells and 5-year recurrence-free survival of patients with tamoxifen-treated breast cancer. Hormones & Cancer 2011, 2:286-297.
36. Sørlie T., Perou C.M., Tibshirani R., Aas T., Geisler S., Johnsen H., et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proceedings of the National Academy of Sciences of the United States of America 2001, 98:10869-10874.
37. Takayama K., Horie-Inoue K., Ikeda K., Urano T., Murakami K., Hayashizaki Y., et al. FOXP1 is an androgen-responsive transcription factor that negatively regulates androgen receptor signaling in prostate cancer cells. Biochemical and Biophysical Research Communications 2008, 374:388-393.
38. Tan S.K., Lin Z.H., Chang C.W., Varang V., Chng K.R., Pan Y.F., et al. AP-2γ regulates oestrogen receptor-mediated long-range chromatin interaction and gene transcription. EMBO Journal 2011, 30:2569-2581.
39. Thorat M.A., Marchio C., Morimiya A., Savage K., Nakshatri H., Reis-Filho J.S., et al. Forkhead box A1 expression in breast cancer is associated with luminal subtype and good prognosis. Journal of Clinical Pathology 2008, 61:327-332.
40. Wang B., Lin D., Li C., Tucker P. Multiple domains define the expression and regulatory properties of Foxp1 forkhead transcriptional repressors. Journal of Biological Chemistry 2003, 278:24259-24268.
41. Wang B., Weidenfeld J., Lu M.M., Maika S., Kuziel W.A., Morrisey E.E., et al. Foxp1 regulates cardiac outflow tract, endocardial cushion morphogenesis and myocyte proliferation and maturation. Development (Cambridge, England) 2004, 131:4477-4487.
42. Wolf I., Bose S., Williamson E.A., Miller C.W., Karlan B.Y., Koeffler H.P. FOXA1: Growth inhibitor and a favorable prognostic factor in human breast cancer. International Journal of Cancer 2007, 120:1013-1022.
43. Zhang Y., Li S., Yuan L., Tian Y., Weidenfeld J., Yang J., et al. Foxp1 coordinates cardiomyocyte proliferation through both cell-autonomous and nonautonomous mechanisms. Genes & Development 2010, 24:1746-1757.